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HIV-InfectedPatients,WithandWithoutHCVCoinfection,
Receiving Boosted or Unboosted Regimens
Mario Regazzi, PharmD,* Paola Villani, BiolD,* Roberto Gulminetti, MD,† Maria Cusato, PharmD,*
Michela Brandolini, MD,† Carmine Tinelli, MD,‡ Alessandra Barassi, MD,§ Renato Maserati, MD,†
Laura Sighinolfi, MD,¶ Antonella D’Arminio Monforte, MD,§ and Gian Vico Melzi D’Eril, MD§
Background: Adequate plasma trough concentrations (Ctrough) of
protease inhibitors are required to maintain antiviral activity
throughout the dosing interval. Therapeutic drug monitoring is used
in clinical practice to optimize dosage and avoid toxic or sub-
therapeutic drug exposure. The pharmacokinetic variability of Ata-
zanavir (ATV) can be relatively large, as a result of several factors.
One of the affecting factors may be hepatic impairment due to
hepatitis C virus (HCV) coinfection.
Methods: We collected trough plasma samples from human im-
munodeficiency virus (HIV)-1–infected outpatients, with and without
HCV coinfection and/or cirrhosis, receiving stable highly active
antiretroviral therapy containing ATV. In the total population, we
mainly compared the 2 regimens: 300ATV + 100RTV OD [ritonavir
(RTV), once daily (OD)] versus 400ATV OD. We used a threshold
value of 0.15 mg/mL, based on the proposed therapeutic range (0.15–
0.85 mg/mL). Plasma concentrations of ATV were determined by
a validated assay using high-performance liquid chromatography
with ultraviolet detection. A total of 214 HIV-infected outpatients
were included. For each regimen, we compared 3 groups of subjects:
HIV+/HCV2, HIV+/HCV+, and HIV+/HCV+ with cirrhosis.
Results: In the whole study population, we observed a large vari-
ability and found suboptimal Ctrough levels (,0.15 mg/mL) in 23 sub-
jects (2 belonging to the 300/100 OD group and 21 to the 400 OD
group). For the standard dosage regimen of 300ATV + 100RTV OD,
we did not find a statistical difference between HIV-infected patients
without HCV coinfection versus HIV-infected patients with HCV
coinfection: median 0.85 (interquartile range 0.53–1.34) and 0.95
(0.70–1.36) mg/mL, respectively. In HIV+/HCV+-infected patients
with cirrhosis, we found a median Ctrough of 0.70 (0.43–1.0) mg/mL,
with no statistical difference when compared with HIV+/HCV2 in-
fected patients. For the 400ATVOD (n = 90) dosage regimen, the total
median ATV Ctrough was 0.40 (0.23–1.0) mg/mL. In this group, we
found a statistically significant difference between HIV+/HCV2 and
HIV+/HCV+-infected patients: median Ctrough was 0.23 (0.11–0.42)
and 0.52 (0.20–1.0)mg/mL, respectively. In HIV+/HCV+ subjects with
cirrhosis, the Ctrough median value was 0.42 (0.13–0.75) mg/mL, and
there was a significant difference when compared with HIV patients
without coinfection.
Conclusions: Therapeutic drug monitoring of ATV in patients
receiving unboosted regimen may be useful to identify those HIV-
infected subjects, with or without HCV coinfection, who may benefit
from adding low RTV doses, or the subset of patients in whom
removal of RTV could be attempted without the risk of suboptimal
plasma ATV exposure.
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INTRODUCTION
The management of human immunodeficiency virus
(HIV) infection is complex, because there is great interpatient
variability in the absorption, distribution and elimination of
antiretroviral agents. Therefore, therapeutic drug monitoring
(TDM) has been proposed as a useful strategy to individualize
therapy for people with HIV.1–4
Protease inhibitors (PIs) are one of the main classes of
antiretroviral drugs recommended for the initial treatment
of HIV-1–infected patients and are often boosted with
ritonavir (RTV), which increases systemic exposure,
reduces the risk of resistance, and decreases the adminis-
tration frequency.5
Atazanavir (ATV) is a potent azapeptide PI, adminis-
trated in combination with other antiretrovirals for HIV-1
treatment. Interpatient variability in ATV pharmacokinetics
is relatively large and may be a result of several factors. One
potential contributing mechanism is hepatic impairment due
to hepatitis C virus (HCV) or hepatitis B virus (HBV)
coinfection, which occurs in approximately 30% of HIV-
infected individuals in the United States and up to 50% in
Mediterranean countries.6,7 Liver impairment caused by
hepatitis infections may impact the absorption of the drug
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and its metabolism, as ATV is extensively metabolized in the
liver, principally by CYP3A4/3A5 hepatic enzymes.
As with other PIs, quantifying and explaining the
variability in ATV exposure by means of TDM are crucial for
better pharmacotherapy management. It has been recently
reported for ATV that both virologic efficacy and toxicity seem
to be concentration dependent. ATV trough concentrations
ranging from 0.15 to 0.85 mg/mL have been shown to give the
highest probability of virologic response and the lowest
probability of side effects.8,9
The objective of this study was to analyze TDM data
obtained during ATV treatment of HIV-infected patients with
and without hepatitis coinfection, receiving boosted or
unboosted regimens, with particular attention to the difference
between the 2 regimens and the potential influence of hepatic
impairment on ATV plasma concentrations.
MATERIALS AND METHODS
Study Population
We performed a multicenter, retrospective, observational
study. We evaluated plasma samples from a cohort of 214 HIV-
1–infected outpatients, with and without HCV/HBV coinfec-
tion and/or cirrhosis, at 3 different Clinical Centers, within the
context of a routine TDM program. All patients were receiving
RTV-boosted or unboosted ATV as part of their antiretroviral
therapy (ART). In addition to dosing- and sampling-time
information, the following data were recorded for each patient:
sex, body weight, age, race, CD4 T-cell count, viral load,
transaminase and bilirubin levels, HCV/HBV coinfection, and
concomitant medications.
The patients were stratified as (1) HIV-infected patients
non-coinfected; (2) HIV-infected patients with chronic
hepatitis (documented by detectable plasma HCV-RNA or
HBV-DNA) without cirrhosis; and (3) HIV-infected patients
with HCV/HBV-related liver cirrhosis.
The diagnosis of cirrhosis was made by assessing the
AST Platelet Ratio Index (APRI) score, a simple test that
employs the aspartate aminotransferase (AST) to platelet ratio
as an indirect marker of hepatic fibrosis. The APRI-positive
predictive value is$1.5, and the negative predictive value, for
excluding significant fibrosis is ,0.5.10
Pharmacokinetic Sampling and
Analytical Method
Pharmacokinetic assays were centralized at the Labo-
ratory of Clinical Pharmacokinetics, Foundation IRCCS San
Matteo Hospital, Pavia, Italy.
ATV plasma concentrations were obtained in the context
of routine drug monitoring and according to the procedures
established at our Institutions. Ethics Committee approval was
not required for studies using routine monitoring data.
To determine Ctrough, blood samples were drawn in the
morning, under steady-state conditions (ie, the drug regimen
was unchanged for at least 1 month), just before therapy
administration. The window for blood sample collection was
22–26 hours. The time of the last ATV dose was ascertained by
patient report. No other specific measure of adherence was
used. Blood samples (5 mL) were collected into lithium heparin
or potassium-ethylenediaminetetraacetic acid Monovette syrin-
ges (Sarstedt, Numbrecht, Germany). Plasma was separated by
centrifugation and virus inactivated in a water bath at 56C for
45 minutes, and stored at 220C until analysis. ATV plasma
concentrations were determined by a validated modified
method using high-performance liquid chromatography with
ultraviolet detection. 11 Briefly, after liquid-liquid extraction in
3 mL of ethyl acetate–hexane, the samples were separated via
reverse-phase liquid chromatography on a Hypersil BDS C18
(4.6 3 250 mm, 5 mm) analytical column under isocratic
conditions (60% H3PO4 0.1% in H2O, pH 7.2: 40%
acetonitrile). UV detection at 220 nm provides adequate
sensitivity with minimal interference from endogenous matrix
components. The calibration curve was linear over a concen-
tration range of 0.05–10 mg/mL with a 0.05-mg/mL limit of
quantification and a lower limit of detection of 0.02 mg/mL.
The method is specific, accurate, and precise. Intraassay
coefficients of variation for ATV quality control concen-
trations were 8.6%, 9.5%, and 9.7% for the low, medium, and
high quality control, respectively. Interassay coefficients of
variation were 7.8%, 8.9%, and 9.1%, respectively. The
corresponding accuracy ranged between 95% and 103%. Our
laboratory is included in an external quality assurance program
(Association for Quality Assessment in TDM and Clinical
Toxicology, The Netherlands).
The proportion of patients with an ATV Ctrough below the
suggested target value of 0.15 mg/mL was estimated. We used
the threshold value of 0.15 mg/mL, based on the previously
proposed therapeutic range (0.15–0.85 mg/mL).12,13 Therefore,
an ATV Ctrough below this value was defined as suboptimal. We
also compared data obtained from the 2 ATV regimens among
the different HIV-infected subject populations, in relation to the
presence of hepatitis coinfection and/or cirrhosis.
Statistical Analyses
Median, lnterquartile range (IQR), and 5–95
percentiles were used to summarize quantitative variables
that were not normally distributed (Shapiro test). Count and
percentage were used for qualitative variables. Differences
between.2 groups were evaluated with the Mann–Whitney
test, whereas differences between .2 patient groups were
assessed by the Kruskall–Wallis test. Corrections for
multiple comparisons were not performed for pairwise
comparison, as the study was intended as exploratory, not
explicative. The Chi-square (x2) test or Fisher exact test was
used for qualitative variables. A P value of ,0.05
was considered statistically significant, and all tests were
2 sided. Data analysis was performed with the STATA
statistical package (Ver. 10.0, 2009, Stata Corporation,
College Station, TX).
RESULTS
A total of 214 HIV-infected outpatients (148 men and
66 women) receiving antiretroviral regimens containing ATV,
were evaluated for ATV Ctrough levels. Patients received
boosted or unboosted ATV once daily, associated with
2 nucleoside reverse transcriptase inhibitors. The most
common regimens prescribed, including 2 nucleoside reverse
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transcriptase inhibitors, were lamivudine plus abacavir,
tenofovir plus emtricitabine, tenofovir plus lamivudine,
lamivudine plus zidovudine, or tenofovir plus didanosine
(didanosine was administered 2 hours after ATV or in an
enteric-coated formulation, to avoid interaction of the
antacid with ATV). No drug known to interact with ATV
therapy was coadministered.12,13
The percentage of patients with an HIV-1 RNA load
,50 copies per milliliter was similar between patients
receiving boosted or unboosted ATV. Overall, the patients
receiving boosted or unboosted ATV therapy were comparable
regarding demographic and clinical characteristics and
concomitant ART. The patients were divided into 3 groups:
HIV+ without coinfection, HIV+/HCV+ and HIV+HCV+
with cirrhosis. Patients’ demographic and clinical character-
istics are reported in Tables1 and 2 (expressed as median, IQR,
and 5–95 percentiles).
We first evaluated the 2 regimens: 300ATV + 100RTV
OD versus 400ATV OD. The first regimen (300/100 OD)
included 124 patients: 73 HIV+/HCV–, 26 HCV+/HCV+, and
25 HIV+/HCV+ with cirrhosis. For the standard dosage of
300ATV + 100RTV OD, the total median ATV Ctrough was
0.90 (IQR 0.43–1.36) mg/mL. We observed a large variability
and found suboptimal Ctrough levels (,0.15 mg/mL) in 2 sub-
jects only, who had no measurable viral load.
The second regimen (400 OD) included 90 subjects: 38
HIV+/HCV–, 28 HIV+/HCV+, and 24 HIV+/HCV+ with
cirrhosis. For the 400ATV OD dosage, the total median ATV
Ctrough was 0.40 (0.23–1.0) mg/mL. We observed a large
variability and found suboptimal Ctrough levels in 21 subjects
(4 patients had measurable viral load, ranging from 677 to
17,180 copies per milliliter).
For each regimen, we compared 3 groups of subjects:
HIV+/HCV2, HIV+/HCV+, HIV+/HCV+ with cirrhosis
(Table 3). In the first regimen (300/100 OD), we did not
find a statistical difference between HIV+ patients without
HCV coinfection versus HIV+ patients with HCV coinfec-
tion: median 0.85 (IQR 0.53–1.34) and 0.96 (0.70–1.36)
mg/mL, respectively. In cirrhotic patients, we found a median
Ctrough of 0.70 (0.43–1.0) m/mL with no statistical difference
when compared with HIV+/HCV2 and with HIV+/HCV+
patients.
In the second regimen group (400 OD), we found
a statistically significant difference between HIV+/HCV2 and
HIV+/HCV+ patients: median Ctrough was 0.23 (IQR 0.11–
0.42) and 0.52 (0.20–1.0) mg/mL, respectively (P = 0.005). In
cirrhotic subjects, the Ctrough median value was 0.42 (0.13–
0.75) mg/mL, and there was a significant difference when
compared with HIV+ patients without coinfection (P = 0.044).
The 400 mg OD unboosted regimen in HIV+/HCV–
subjects provided significantly lower ATV trough concentra-
tions than did the standard dosage of 300ATV+100RTV OD
(median 0.23 versus 0.85 mg/mL; P , 0.0001). The same
difference between the 2 ATV regimens was also confirmed in
HIV+/HCV+ patients (0.52 mg/mL for the 400 OD and 0.96
mg/mL for the 300/100 OD, respectively).
Cirrhotic patients had a slightly lower Ctrough median
value in the 300/100 OD regimen (0.70 mg/mL) but a higher
median value in the 400 OD regimen (0.42 m/mL), when
compared with the HIV+/HCV2 patient groups (0.85 and
0.23 mg/mL, respectively).
DISCUSSION
We report the results of an observational study using
TDM as a surveillance tool to monitor ATV therapy in the
clinical setting. ATV is approved in Europe and in the United
States at a dose of 300 mg boosted with 100 mg of RTVonce
daily (ATV/RTV 300/100 mg OD) to be taken with food, but it
is also approved unboosted at 400 mg once daily for treatment-
naive patients.12,13 In patients with hepatic impairment, ATV
should be used with caution in the case of mild to moderate
dysfunction (Child–Pugh category A) and the oral ATV dose
needs to be adjusted in moderate impairment (Child–Pugh
category B), with a reduction to 300 mg daily. For severe
hepatic impairment (Child–Pugh category C), ATV is not
recommended. RTV-boosted ATV regimens should be used
with caution in patients with mild hepatic impairment and
should not be used in those with moderate to severe hepatic
impairment.12,13 The dosage precautions for the use of ATV in
these clinical situations are based on limited available
pharmacokinetic and safety data in subjects with hepatic
impairment, for both regimens.
The results of our pharmacokinetic study, obtained from
the comparison of the 2 regimens, confirm the large
interindividual variability in ATV Ctrough, particularly with
the 400 OD regimen. The data also illustrate how ATV trough
levels in plasma may be lower than the proposed target
concentration, particularly when it is not boosted with low-
dose RTV. This observation is in accordance with the results of
Stohr et al,14 who found that there is a high probability of an
ATV trough concentration below the recommended therapeu-
tic range with the unboosted 400-mg regimen. Also, in
keeping with the findings of Flexner,15 we observed that the
high variability in the ATV plasma concentrations may be
reduced, but not eliminated, with RTV boosting. High ATV
interindividual variability has also been demonstrated in
several previous studies.2,16,17
Our results are similar to those of Winston et al who
evaluated ATV Ctrough concentrations in a cohort of patients
with HIV-1 (n = 100) and found a mean ATV value of 0.28
(95% confidence interval 0.095–0.47) mg/mL (n = 19) in
nonboosted regimens and a mean ATV value of 0.77 (95%
confidence interval 0.65–0.90) mg/mL (n = 81) in RTV-
boosted regimens.18 Another study by Agarwala et al19
reported a mean of 0.27 and 0.86 mg/mL for nonboosted
and boosted regimens, respectively.
ATV is extensively metabolized in the liver, principally by
CYP3A4/3A5 enzymes, and hepatic impairment may contribute
to ATV variability. Thus, it is difficult to predict the impact of
liver disease on the metabolism and pharmacokinetics and to
provide general dosing guidelines for these subjects.20,21 The
situation is further complicated by the presence or the absence
of the RTV booster effect, and the results are controversial.
Data on the incidence of liver toxicity due to ATV/
RTV, in the specific subset of HIV/hepatitis coinfected
individuals, are very limited and come from relatively small
populations.14,22 Available data recommend avoiding
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ATV/RTV in patients with cirrhosis and moderate to severe
hepatic insufficiency although Barreiro et al23 suggest that this
recommendation should be reconsidered. Our data are in
agreement with those of other studies reporting that hepatic
impairment does alter the pharmacokinetics of ATV.13,24
In our patients, the 400 mg OD unboosted regimen in
HIV+/HCV-negative subjects provided significantly lower ATV
trough concentrations than did the standard dosage of 300ATV +
100RTV OD (median 0.23 versus 0.85 mg/mL; P , 0.0001).
The same difference between the 2 ATV regimens was also
confirmed in HIV+/HCV-positive patients (0.52 mg/mL for the
400 OD and 0.96 mg/mL for the 300/100 OD, respectively).
Cirrhotic patients had a slightly lower Ctrough median value in
the 300/100 OD regimen (0.70 mg/mL) but a higher median
value in the 400 OD regimen (0.42 mg/mL) when compared
with HIV+/HCV-negative patient groups (0.85 and 0.23
mg/mL, respectively). It should be underscored that even
considering the elevated levels in cirrhotic and HCV-negative
patients, the concentrations obtained with the 400-mg
unboosted regimen were lower than the corresponding
concentrations obtained with the 300/100 boosted regimen.
In the unboosted 400-mg regimen (Table 3), there was
a statistically significant difference between HIV patients with
normal hepatic function and HIV+/HCV+-infected patients with
or without cirrhosis. In this group of coinfected subjects, hepatic
dysfunction may lead to significantly higher ATV plasma levels,
when compared with normal HIV-infected subjects.
In our study, in contrast to the data obtained in the ATV
400-mg unboosted regimen, in the 300/100 regimen, the
3 groups of patients (HIV+/HCV2, HIV+/HCV+, and
HIV+/HCV+ with cirrhosis) had similar trough concentrations.
The absence of a statistical difference in trough plasma
concentrations among the 3 groups of patients on the boosted
regimen 300/100 may be explained by the presence of RTV,
which inhibits hepatic metabolism, and thus the expected
reduction in clearance for patients with hepatic dysfunction may
be absent or less pronounced. Results from other studies
support the concept that the intrinsic clearance of PIs in patients
with liver disease is only partially affected after being inhibited
by low-dose RTV coadministration, because no significant
changes in drug pharmacokinetics in mild liver dysfunction
with morphologic evidence of cirrhosis were observed.23–27
This PK study has some limitations. First of all, it was
based on a retrospective observational TDM data set and not
on a controlled protocol. Also, the potentially confounding
impact of other drug therapy, such as coadministration of
tenofovir [tenofovir disoproxil fumarate (TDF)] was not
addressed in our analysis, as the presence of this nucleotide
analog reverse transcriptase inhibitor in the concomitant
therapy was equally distributed among all patient groups;
TABLE 1. Characteristics of the Study Population Receiving ATV 300/100rtv OD Regimen, Median (IQR)
Characteristics HIV (n = 73) HIV/HCV (n = 26) HIV/HCV Cirrhosis (n = 25)
Sex M/F 47/26 19/7 21/4
Age (yrs) 45 (41–50) 45 (42–46) 47 (41–48)
Weight (kg) 68 (56–73) 65 (53–78) 77 (55–85)
CD4+ (cells per cubic millimeter) 501 (335–666) 463 (382–661) 512 (357–665)
Plasma HIV load ,50 copies per milliliter (%) 91 92 96
ALT (IU/L) 24 (17–32) 31 (20–44) 60 (37–107)
AST (IU/L) 24 (19–29) 33 (23–52) 55 (32–80)
Albumin (g/dL) 4.25 (4.16–4.43) 4.28 (4.17–4.5) 4.14 (4.12–4.18)
Total bilirubin (mg/dL) 2.62 (1.48–3.88) 2.84 (2.32–4.78) 2.87 (2.08–3.94)
Plt (cells per cubic millimeter) 219,500 (186,500–262,000) 228,000 (216,000–258,000) 138,000 (125,000–165,000)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Plt, platelet count.
TABLE 2. Characteristics of the Study Population Receiving ATV 400 OD Regimen, Median (IQR)
Characteristic HIV (n = 38) HIV/HCV (n = 28) HIV/HCV Cirrhosis (n = 24)
Sex M/F 21/17 23/5 17/7
Age (yrs) 41 (38–48) 45 (42–48) 45 (41–53)
Weight (kg) 65 (53–78) 73 (60–78) 65 (57–78)
CD4+ (cells per cubic millimeter) 574 (466–688) 626 (432–811) 488 (333–656)
Plasma HIV load ,50 copies per milliliter (%) 81 89 83
ALT (IU/L) 27 (17–48) 51 (23–73) 71 (49–88)
AST (IU/L) 21 (17–29) 42 (26–51) 59 (41–80)
Albumin (g/dL) 4.1 (4.13–4.45) 4.0 (3.9–4.4) 3.8 (2.5–3.9)
Total bilirubin (mg/dL) 1.59 (0.9–2.68) 2.2 (1.1–3.5) 1.8 (1.32–2.42)
Plt (cells per cubic millimeter) 232,000 (210,000–265,000) 235,500(148,000–286,000) 135,000 (112,500–165,000)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Plt, platelet count.
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notably, the proportion of HIV patients with and without
coinfection treated with TDF was essentially similar (61%
versus 49%, respectively). In addition, the literature data report
conflicting results on the effect of TDF on ATV exposure: In
some studies, ATV exposure was decreased by TDF, in both
boosted and unboosted regimens28,29, but in other observa-
tional studies, no influence was found.14,30
However, the results of this observational study should
contribute to ATV therapy monitoring, as they reflect real-life
clinical settings in a particular population, HIV/HCV-
coinfected patients, with or without cirrhosis, in which there
are limited and contrasting PK data.
When we analyzed the plasma concentrations of the
2 therapy regimens in relationship to the reference target
concentration (0.15 mg/mL), in the nonboosted regimen, the
percentage of patients with a plasma level (Ctrough) below the
target concentration was elevated (26%) with respect to the 2%
observed in the boosted regimen. However, in HIV+/HCV+-
infected patients receiving unboosted regimen, only 14% had
suboptimal plasma levels. Our data confirm that TDM offers
useful additional information in support of ATV individualized
dose adjustment.
From a pharmacokinetic point of view, HIV subjects,
with or without HCV coinfection and/or cirrhosis (mild–
moderate), will have increased exposure when adding low-dose
RTV, but in a subset of patients, the removal of RTV could be
attempted without risking suboptimal plasma ATV exposure
and subsequent virological failure. At present, only TDM can
differentiate between these 2 very distinct situations.
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